Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: An update

Onkologie

Volumn 29, Issue 5, 2006, Pages 210-217

  Paepke, Stefan ^a,e   Jacobs, Volker R ^a   Paepke, Daniela ^a   Euler, Uta ^a   Blohmer, Jens Uwe ^b   Warm, Mathias ^c   Ohlinger, Ralf ^d   Fischer, Torsten ^a   Kiechle, Marion ^a   Harbeck, Nadia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

AGO guidelines; Breast cancer, receptor positive; Clinical trials; Recommendations; Therapy, primary endocrine

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; EXEMESTANE; LETROZOLE; PACLITAXEL; PROGESTERONE; PROGESTERONE RECEPTOR; TAMOXIFEN;

AGE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; ENDOMETRIUM CANCER; FATIGUE; HIGH RISK PATIENT; HOT FLUSH; HUMAN; METABOLIC DISORDER; OVERALL SURVIVAL; POSTMENOPAUSE; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TUMOR VOLUME;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PRACTICE GUIDELINES; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 33646528648     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092267     Document Type: Review

References (62)

1. Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674.
2. Silliman RA: What constitutes optimal care for older women with breast cancer? J Clin Oncol 2003;21:3554-3556.
3. Fisher B, Bryant, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672.
4. Eiermann W, Paepke S, Appfelstedt J, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-1532.
5. Semiglazov VF, Semiglazov W, Ivanov VG, et al: Neoadjuvant endocrine therapy: exemestane (E) vs tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4 N0-1-2 M0). Breast Cancer Res Treat 2003;82(suppl 1):111.
6. Paepke S, Bouterfa H, Wallwiener D, The Fem D1 Study Group: A multicenter study of preoperative treatment with Femara (letrozole) for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast Cancer. Breast Cancer Res Treat 2001;69:453.
7. Smith I, Dowsett M, on behalf of the IMPACT Trialists: Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen-receptor positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat 2003;82(suppl 1):6.
8. Valero V, Hoff PM, Singletary SE, et al: Combined modality treatment of locally advanced breast cancer (LABC) in elderly patients (PTS) using tamoxifen (TAM) as primary therapy. Proc Am Soc Clin Oncol 1989;17:S15.
9. Geisler J, King N, Anker G, et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cane Res 1998;4:2089-2093.
10. Lonning PE: Pharmacology of new aromatase inhibitors. Breast 1996;5:202-208.
11. Friedrichs K: Empfehlungen zur endokrinen Therapie des metastasierten Mammakarzinoms; in: Aktuelle Empfehlungen zur Therapie primärer und fortgeschrittener Mammakarzinome. State of the Art Meeting Gravenbruch 2002. München, Zuckschwerdt Verlag, 2002, pp 144-152.
12. Paepke S, Kiechle M: Palliative therapy of breast cancer. Onkologie 2003;26(suppl 7):4-10.
13. Mustacchi G, Milani S, Pluchinotta A, et al: Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 1994;14:2197-2200.
14. Gazet LC, Ford HT, Coombes RC, et al: Prospective randomized trial of tamoxifen versus surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994; 20:207-214.
15. Robertson LF, Ellis IO, Elston CW, et al: Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up: Eur J Cancer 1992;3:582-587.
16. Milla-Santos A, Milla I, Rallo L: Anastrozole (A) as neoadjuvant (NEO) therapy for hormone-dependent locally advanced breast cancer (LABC) in postmenopausal (PM) pts. Breast Cancer Res Treat 2001;69:302.
17. Miller WR, Santen RJ: Aromatase Inhibition and Breast Cancer. New York, Marcel Dekker, 2001, pp 29-51.
18. Anderson EDC, Forrest AP Levack P, et al: Response to endocrine manipulation and estrogen receptor concentration in large operable primary breast cancer. Br J Cancer 1989;60:223-226.
19. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double blind, single center study. Clin Cancer Res 2000;6:2229-2235.
20. Geisler J: Arimidex - direkte Wirkung auf Tumoröstrogenspiegel. Akt Onkol 2000;108:9-15.
21. Geisler J, Detre S, Berntsen H, et al: Influence of neoadjuvant Anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res 2001;7:1230-1236.
22. Dowsett M, Ebbs SR, Dixon M, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: influence of hormonal status and Her-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 2005;11:2477-2492.
23. Dowsett M, on behalf of the IMPACT trialists: Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cancer Res Treat 2003;82(suppl 1):6.
24. Murray J, Young O, Renshaw L, et al: Letrozole and Anastrozole: a preoperative study of their effects on ER positive breast cancer in postmenopausal women. Breast Cancer Res Treat 2004:S37.
25. Dowsett M, IE Smith, for the IMPACT Trialists: Molecular effects of anastrozole and tamoxifen alone and combined in the IMPACT trial of neoadjuvant of primary breast cancer. Proc Am Soc Clin Oncol 2004;23:11.
26. Smith I, Dowsett M, Ebbs SR, et al: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, or combined with tamoxifen (IMPACT) multicenter double blind randomized trial. J Clin Oncol 2005;22:1-9.
27. Miller WR, Dixon JM: Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002;9:9-15.
28. Chow LWC, Toi M, Takebayashi Y, et al: Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: second report. Breast Cancer Res Treat 2003;82(suppl 1):101.
29. Gil Gil MJ, Barnadas A, Cirera L, et al: Primary hormonal therapy with exemestane in patients with breast tumors > 3cm in diameter: results of a Spanish multicenter phase II trial. Proc Am Soc Clin Oncol 2004;23:27.
30. Tubiana-Hulin M, Spyratos F, Becette V, et al: Phase II study of neo-adjuvant exemestane in post-menopausal patients with operable breast cancer. Breast Cancer Res Treat 2003;82(suppl 1):106.
31. Tubiana-Hulin M, Spyratos F: Response to neo-adjuvant exemestane in post-menopausal breast cancer patients: correlation with biological factors measured by real-time quantitative RT-PCR. Proc Am Soc Clin Oncol 2004; abstr 538.
32. Sokol L: Our first experience with preoperative treatment of postmenopausal locally advanced breast cancer patients with Letrozole. Proc Am Soc Clin Oncol 2003; abstr 319.
33. Jackson J, White S, Dixon M, et al: Short- and long-term effects of letrozole on tumor histopathology and immunopathology in patients with breast cancer given neoadjuvant treatment. Breast Cancer Res Treat 2003;82(suppl 1):102.
34. Anderson TJ, Dixon MJ, Murray J, et al: Early changes in tumour Ki67 expression differentiate for pathological (but not clinical) response in breast cancers treated neo-adjuvantly with letrozole. Breast Cancer Res Treat 2004;50.
35. Turner J, Bentey R, Tao Y, et al: Changes in tumor grade with neoadjuvant endocrine therapy: morphological evidence for fundamental differences in the anti-tumor effects of letrozole and tamoxifen. Breast Cancer Res Treat 2004;S37.
36. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-1736.
37. Arpino G, Green SJ, Allred DC, et al: Her-2 amplification, Her-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cane Res 2004;10:5670-5676.
38. Baselga J, Gianni L, Geyer C, et al: Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004;31:51-57.
39. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;18:3808-3816.
40. Paepke S, Bouterfa H, Wallwiener D: A multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer. Proc Am Soc Clin Oncol 2003; abstr 321.
41. Paepke S, Tulusan AH, Kiesel L, et al: A multi-center study of pre-operative treatment with letrozole (L) for optimal duration of treatment in post-menopausal women with ER and/or PgR positive breast cancer. Ann Oncol 2004;15(suppl 3):64.
42. Renshaw L, Murray J, Young O, et al: Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat 2004;36.
43. Von Minckwitz G, Costa S, Raab G, et al: Dose dense doxorubicin, docetaxel and granulocyte colony stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase II b study. J Clin Oncol 2001;19:3506-3515.
44. Von Minckwitz G, Raab G, Schutte M, et al: Preoperative chemotherapy in primary operable breast cancer with a dose dense combination of doxorubicin and docetaxel (Adoc) - experience of the GEPARDO-GABG study group. Zentralbl Gynakol 2001;123:497-504.
45. Von Minckwitz G, Raab G, Caputo A, et al: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23:2676-85.
46. Krainick U, Astner A, Jonat W, Wallwiener D: Phase II study to define safety and efficacy of exemestane as preoperative therapy for post-menopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative GENARI). Breast Cancer Res Treat 2003;82(suppl 1):55.
47. Wolf C, Ortmann O, Wallwiener D, et al: GENARI-Ein Studienkonzept zur Prüfung von Verträglichkeit, Wirksamkeit und Nutzen einer chemoendokrinen präoperativen Behandlung mit Exemestan. Geburtshilfe Frauenheilkd 2002;62:333-338.
48. Lichtenegger W, Hackl W, Hüttner C: Exemestane combined with weekly docetaxel as preoperative treatment for breast cancer. Proc Am Soc Clin Oncol 2001; abstr 1832.
49. Semiglazov VF, Semiglazov V, Ivanov V, et al: The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol 2004; abstr 519.
50. Semiglazov VF, Semiglazov V, Ivanov V, et al: Neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER positive breast cancer. Breast Cancer Res Treat 2004;88(suppl 1):106.
51. Baum M, ATAC Trialist Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-2139.
52. Thürlimann B, BIG 1-98 Collaborative Group: Letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: A prospective randomized double blind phase III study. Breast 2005;14(suppl 1):S4.
53. Coombes RC, Hall E, Gibson LJ, et al for IES: A randomized trial of exemestane after two to three years of tamoxifen in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:356-361.
54. Jakesz R, Kaufmann M, Gnant M, et al: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG trial 8 and the ARNO 95 trial. Breast Cancer Res Treat 2004;88 (suppl 1):7.
55. Goss P, Ingle JN, Marino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1482-1496.
56. Vyzula R, Dusek L, Zaloudik J, et al: Breast cancer and neoadjuvant therapy: any predictive marker ? Neoplasma 2004;51:471-480.
57. Gaskell DJ, Hawkins RA, de Carteret, et al: Indications for primary tamoxifen therapy in elderly women with breast cancer. Br J Surg 1992;79:1317-1320.
58. Bergman L, van Dongen JA, van Ooijen B, et al: Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Breast Cancer Res Treat 1995;34:77-83.
59. Von Minckwitz G: Taxanes in primary systemic treatment of breast cancer. Onkologie 2003;26 (suppl 7):21-26.
60. AGO-Leitlinien: www.ago-online.de.
61. Van Dalsen AD, de Vries J: Treatment of breast cancer in elderly patients. J Surg Oncol 1995;60:80-82.
62. Miller WR, Dixon JM: Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000;1(suppl 1):9-14.